The Innovation Series: Expand Your Phase I Clinical Trial

Expand Your Phase I Clinical Trial

Please join CLSI, Nucleus Network, and guests for an educational presentation on expediting your Phase 1 Clinical Trial in Australia.

Some compelling benefits for consideration are:

• Speed – you can have First-patient-in, in about 6 weeks, and you do not need an IND to commence
• Quality – Data generated is accepted by the FDA and EMA. Many file IND after Phase 1 with Data in hand.
• Cost – There is a 41% cash rebate for all work performed in Australia

Program Agenda

5:00pm Registration Opens

5:30pm Opening Remarks | Lori Lindburg, President & CEO, CLSI

5:40pm Panel Discussion

6:40pm Audience Q&A

7:00pm Networking Reception

Panelist

Cameron Johnson
Chief Executive Officer and Managing Director, Nucleus Network

Cameron Johnson joined Nucleus Network in 2013 initially as the Chief Operating Officer before moving to the Chief Executive Officer position. Prior to working for Nucleus, Cameron was Chief Executive Officer of a Phase 1 Clinical Trials Organisation. Ultimately responsible for the growth and success of the company, he led the organization to win the 2013 Western Australia’s Industry and Export Premiers Award for Excellence. Other awards include Western Australia’s Industry and Export Award for Healthcare and Biotechnology and Western Australia’s Industry and Export Award for Emerging Exporter of 2012.

Cameron has worked extensively in early phase clinical trials across Australia, Europe, and the US for over 17 years. He is a member of the Australian Institute of Company Directors and The Executive Connection (TEC).

Stewart Walker
Vice President for North America, CoSec

With nearly a decade of hands-on experience in corporate governance and compliance, Stewart Walker has a strong record of supporting US-based executives to navigate various regulatory landscapes.

Stewart understands that a complex web of regulatory and reporting requirements can demand more time from executives than actually running their businesses, and he is happy to represent CoSec--a company that is committed to understanding its clients’ compliance and governance needs, fulfilling their regulatory obligations, and optimizing every opportunity that the Australian market has to offer.

Prior to working at CoSec, Stewart was Director of Sales at RDG Filings, where he spent eight years overseeing sales and customer service for one of the largest Securities & Exchange Commission filing agents.

Ryan Maynard
CFO, Blade Therapeutics

Ryan has over 16 years of biopharmaceutical executive financial leadership experience, and was previously Executive Vice President and CFO of Rigel Pharmaceuticals, Inc. (Nasdaq - RIGL), which is a commercial stage drug development company. During his tenure at Rigel, Ryan raised over $700 million through numerous follow-on public offerings, which supported Rigel’s research and development of small molecules inhibitors for auto-immune diseases and oncology, including their lead asset (Tavalisse) that is approved for Immune Thrombocytopenia Purpura. Ryan serves on the board of Iovance Biotherapeutics (Nasdaq - IOVA), which is focused on cell therapy for oncology indications. He started his career at Ernst & Young LLP, and holds a B.S. in Commerce – Accounting from Santa Clara University.

In Partnership With: